MabThera/Rituxan

The good, the bad and the ugly

The main drivers of revenue for Roche are well-established, standard-of-care blockbuster oncology drugs including Rituxan, Herceptin and Avastin. ... Humira remains at the top, but Celgene’s Revlimid has jumped ahead of Roche’s Avastin, MabThera and

NICE backs Roche’s Gazyvaro after initial rejection

clinical profile justified premium pricing over Mabthera (rituximab), Roche’s older drug for the FL indication. ... Like MabThera, Gazyvaro targets the CD20 receptor but has been designed with sugar molecule side chains that improve its therapeutic and

Roche faces biosimilar blitz in 2018

Novartis’ unit Sandoz and Celltrion/Mundipharma’s Truxima have also claimed a European approval for its biosimilar versions of Roche’s immunotherapy drug MabThera (rituximab). ... Additionally, Rituxan is expected to plummet by 16% to CHF 6.1bn

Novartis doubles down on biosimilars with Biocon alliance

In the last couple of years it has picked up approvals for Rixathon - a biosimilar of Roche’s cancer and arthritis drug MabThera (rituximab) - as well as its Erelzi version of

Roche buys cancer company Ignyta for $1.7bn

It has been bolstering its oncology pipeline in particular as three of its top-selling drugs – Avastin, Herceptin and Rituxan – are starting to face biosimilar competition.

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]